Loading...
Loading...
ALDX| Name | Value |
|---|---|
| Revenues | 0.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 0.0M |
| Operating Expense | 16.1M |
| Operating I/L | -16.1M |
| Other Income/Expense | 1.0M |
| Interest Income | 1.5M |
| Pretax | -15.1M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -15.1M |
Aldeyra Therapeutics, Inc. is a biotechnology company specializing in the development and commercialization of medicines for immune-mediated ocular and systemic diseases. The company's primary focus is on its lead product candidate, reproxalap, a reactive aldehyde species (RASP) modulator, currently in Phase III clinical trials for the treatment of dry eye diseases and allergic conjunctivitis. Additionally, the company is developing ADX-629, a first-in-class orally administered RASP modulator in Phase II clinical trials for psoriasis, asthma, and COVID-19, as well as ADX-2191, a dihydrofolate reductase inhibitor in Phase III for the prevention of proliferative vitreoretinopathy and Phase II for the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma.
